With its Q3 2025 results on Tuesday, Aurinia Pharmaceuticals (AUPH) said that it recently responded to an information request ...
A lawsuit filed against George Tidmarsh, who resigned from a top FDA post on Sunday, includes a series of incendiary texts ...
An alleged extortion attempt, a petty yearslong grudge, shocking social media posts, and ominous text messages make up the ...
2h
Aurinia Pharmaceuticals Inc (AUPH) Q3 2025 Earnings Call Highlights: Strong Lupkynis Sales and ...
Aurinia Pharmaceuticals Inc (AUPH) reports significant growth in Lupkynis sales and raises its 2025 sales guidance, while navigating legal and regulatory hurdles.
Aurinia's Q3 2025 saw 27% LUPKYNIS sales growth and raised 2025 guidance. Discover key earnings insights, clinical updates, and pipeline progress.
Less than 24 hours after resigning his post as the FDA’s head drug regulator, George Tidmarsh is reportedly reconsidering his decision and vowing to fight for his name and credibility amid a probe ...
The administration, as well as HHS, publicly praised Marty Makary’s leadership despite persistent upheaval at the agency.
George Tidmarsh, the newly installed director of the FDA’s Center for Drug Evaluation and Research, was placed on leave ...
The resignation of head drug regulator George Tidmarsh comes amid concerns about conduct related to the lupus nephritis drug ...
On a per-share basis, the Edmonton, Alberta-based company said it had profit of 23 cents. The biotechnology company posted revenue of $73.5 million in the period, beating Street forecasts. Three ...
Dr. George Tidmarsh, the FDA drug regulator who was placed on leave and complained of a “toxic” work environment in an ...
The top drug regulator at the Food and Drug Administration (FDA) resigned Sunday, according to officials, after being accused ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback